Donnerstag, 19. Oktober 2017


  • Pressemitteilung BoxID 72731

4SC announces Conference Call on 6 November 2008 to present Third Quarter Financial Results

Planegg-Martinsried, Germany, (lifePR) - 4SC AG (Frankfurt: Prime Standard: VSC) will publish its third quarter and first nine months 2008 results on 6 November 2008. Thus, at 2:00 p.m. CET (8:00 a.m. EST), the Management Board of 4SC AG will host a public conference call in English language to present the financial results and all important highlights of this period.

Participants of the conference call can dial in under the following numbers and with the passcode 8055447.

Participants from Europe: +49 (0)89 2030 3245 or +44 (0)20 7138 0840
Participants from the U.S.: +1 718 354 1362

Simultaneously to the call, the presentation slides can be followed via internet under http://www.euvisioncast.com (Meeting ID: 8055447; Meeting Password: pw4256).

Please dial in ten minutes before the beginning of the conference.

Approximately two hours after the live presentation, an audio replay of the conference will be available on the "investors" section of the homepage www.4sc.com.

4SC AG

4SC AG (ISIN DE0005753818) has been listed in the Prime Standard of Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with a staff of 77 employees, the company develops novel drug candidates against inflammatory diseases and cancer. 4SC AG utilises its patent protected platform, to create a sustainable project pipeline of drug candidates, which are to be developed up to clinical efficacy in early clinical phases ("proof of concept") and subsequently partnered with the pharmaceutical industry in return for advance and milestone payments as well as royalties. There are currently eight projects in the development pipeline and a rich pool of further discovery projects. Clinical phase IIa for the first project for the treatment of rheumatoid arthritis has already successfully been completed. An additional project for the treatment of various cancers is currently completing a clinical phase I trial. Further projects are in advanced pre-clinical stages.

Further information is to be found at www.4sc.com.

Diese Pressemitteilungen könnten Sie auch interessieren

Initial Coin Offering (ICO) in Deutschland unmöglich?

, Finanzen & Versicherungen, CLLB Rechtsanwälte Cocron, Liebl, Leitz, Braun, Kainz Partnerschaft mbB

Die Währungsbehörde in Singapur (MAS) erklärte im August 2017, dass die Ausgabe digitaler Token in Singapur nunmehr durch die MAS reguliert wird,...

Jetzt noch schnell zum Zahnarzt

, Finanzen & Versicherungen, uniVersa Versicherungen

Regelmäßige Zahnkontrolle hilft nicht nur zur Vorbeugung und Früherkennung von Mund- und Zahnerkrankungen, sondern zahlt sich auch finanziell...

Ammerländer Versicherung ist „Fairster Hausratversicherer“

, Finanzen & Versicherungen, Ammerländer Versicherung VVaG

Kunden sehen die Ammerländer Versicherung als fairen Hausratversicherer. In einer Befragung des Magazins FOCUS Money und der Analyse- und Beratungsgesellschaf­t...

Disclaimer